Keating C. Ken Warren and the Rockefeller Foundation’s Great Neglected Diseases Network, 1978–1988: the transformation of tropical and global medicine. Mol Med. 2014;20 Suppl 1:S24–30.
World Health Organization. Neglected Tropical Diseases. www.who.int/neglected_diseases/. Accessed 2 Mar 2016.
Zijlstra EE, van de Sande WWJ, Fahal AH. Mycetoma: a long journey from neglect. PLoS Negl Trop Dis. 2016;10:e0004244.
European Commission. EU research fighting the three major deadly diseases: HIV/AIDS, malaria and tuberculosis. https://ec.europa.eu/research/health/infectious-diseases/poverty-diseases/doc/prd-catalogue-fp7_en.pdf. Accessed 2 Mar 2016.
Molyneux DH, Hotez PJ, Fenwick A. 'Rapid-impact interventions': how a policy of integrated control for Africa’s neglected tropical diseases could benefit the poor. PLoS Med. 2005;2:e336.
Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. Control of neglected tropical diseases. N Engl J Med. 2007;357:1018–27.
World Health Organization. London declaration on neglected tropical diseases. http://www.who.int/neglected_diseases/London_Declaration_NTDs.pdf. Accessed 2 Mar 2016.
Parkinson T. The impact of genomics on anti-infectives drug discovery and development. Trends Microbiol. 2002;10(10 Suppl):S22–6.
Horn D, Duraisingh MT. Antiparasitic chemotherapy: from genomes to mechanisms. Annu Rev Pharmacol Toxicol. 2014;54:71–94.
Pradhan A, Siwo GH, Singh N, Martens B, Balu B, Button-Simons KA, et al. Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery. Sci Rep. 2015;5:15930.
Das S, Freier A, Boussoffara T, Das S, Oswald D, Losch FO, et al. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med. 2014;6:234ra56.
Bhattacharyya T, Brooks J, Yeo M, Carrasco HJ, Lewis MD, Llewellyn MS, et al. Analysis of molecular diversity of the Trypanosoma cruzi trypomastigote small surface antigen reveals novel epitopes, evidence of positive selection and potential implications for lineage-specific serology. Int J Parasitol. 2010;40:921–8.
Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, et al. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 2011;21:2143–56.
Lamberton PHL, Crellen T, Cotton JA, Webster JP. Modelling the effects of mass drug administration on the molecular epidemiology of schistosomes. Adv Parasitol. 2015;87:293–327.
Manske M, Miotto O, Campino S, Auburn S, Almagro-Garcia J, Maslen G, et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature. 2012;487:375–9.
Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, Viveiros M, et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014;5:4812.
Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine. N Engl J Med. 2015;373:2025–37.
Abdallah AM, Hill-Cawthorne GA, Otto TD, Coll F, Guerra-Assunção JA, Gao G, et al. Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations. Sci Rep. 2015;5:15443.
Guler R, Brombacher F. Host-directed drug therapy for tuberculosis. Nat Chem Biol. 2015;11:748–51.
Zumla A, Maeurer M, Chakaya J, Hoelscher M, Ntoumi F, Host-Directed Therapies Network, et al. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov. 2015;14:511–2.
Khor CC, Hibberd ML. Host-pathogen interactions revealed by human genome-wide surveys. Trends Genet. 2012;28:233–43.
Bains RK. African variation at cytochrome P450 genes: evolutionary aspects and the implications for the treatment of infectious diseases. Evol Med Public Health. 2013;2013:118–34.
Baxter K, Horn E, Gal-Edd N, Zonno K, O’Leary J, Terry PF, et al. An end to the myth: there is no drug development pipeline. Sci Transl Med. 2013;5:171cm1.
Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH. Target assessment for antiparasitic drug discovery. Trends Parasitol. 2007;23:589–95.
Gamo F-J, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera J-L, et al. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010;465:305–10.
Peña I, Pilar Manzano M, Cantizani J, Kessler A, Alonso-Padilla J, Bardera AI, et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci Rep. 2015;5:8771.
Stefanakis, R., Robertson AS, Ponder EL, Moree M. Analysis of Neglected Tropical Disease Drug and Vaccine Development Pipelines to predict Issuance of FDA priority Review Vouchers over the next decade. PLoS NTDs 2012. doi:10.1371/journal.pntd.0001803
Mullard A. Priority review voucher pitfalls. Nat Rev Drug Discov. 2015;14:811.
Burrows JN, van Huijsduijnen RH, Möhrle JJ, Oeuvray C, Wells TNC. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.
Pedrique B, Strub-Wourgaft N, Some C, Olliaro P, Trouiller P, Ford N, et al. The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment. Lancet Glob Health. 2013;1:e371–9.
Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6:29–40.
Tommasi R, Brown DG, Walkup GK, Manchester JI, Miller AA. ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov. 2015;14:529–42.
Balasegaram M, Bréchot C, Farrar J, Heymann D, Ganguly N, Khor M, et al. A global biomedical R&D fund and mechanism for innovations of public health importance. PLoS Med. 2015;12:e1001831.
The State of the World’s Antibiotics, 2015 | Center for Disease Dynamics, Economics & Policy (CDDEP). http://cddep.org/publications/state_worlds_antibiotics_2015#sthash.JFG2IifK.dpbs. Accessed 26 Feb 2016.
Zumla AI, Gillespie SH, Hoelscher M, Philips PPJ, Cole ST, Abubakar I, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis. 2014;14:327–40.
Medicines for Malaria Venture. Interactive R&D portfolio. http://www.mmv.org/research-development/rd-portfolio. Accessed 2 Mar 2016.
Chatelain E, Konar N. Translational challenges of animal models in Chagas disease drug development: a review. Drug Des Devel Ther. 2015;9:4807–23.
Mikolajczak SA, Vaughan AM, Kangwanrangsan N, Roobsoong W, Fishbaugher M, Yimamnuaychok N, et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe. 2015;17:526–35.
Manns MP, von Hahn T. Novel therapies for hepatitis C—one pill fits all? Nat Rev Drug Discov. 2013;12:595–610.
Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today. 1988;4:112–5.
Hotez P. Mass drug administration and integrated control for the world’s high-prevalence neglected tropical diseases. Clin Pharmacol Ther. 2009;85:659–64.
Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015;93:125–34.
Tiono AB, Ouédraogo A, Ogutu B, Diarra A, Coulibaly S, Gansané A, et al. A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J. 2013;12:79.
WHO Collaborating Centre for Advocacy & Training in Pharmacovogilance. Pharmacovigilance. http://www.who-pvafrica.org/index.php/pharmacovigilance/. Accessed 2 Mar 2016.
Hussain MA, Sitha AK, Swain S, Kadam S, Pati S. Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infect Dis Poverty. 2014;3:31.
malERA Consultative Group on Health Systems and Operational Research. A research agenda for malaria eradication: health systems and operational research. PLoS Med. 2011;8:e1000397.
Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ. 1998;76 Suppl 2:22–5.
Chu BK, Deming M, Biritwum N-K, Bougma WR, Dorkenoo AM, El-Setouhy M, et al. Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop Dis. 2013;7:e2584.
Aiken AM, Davey C, Hargreaves JR, Hayes RJ. Re-analysis of health and educational impacts of a school-based deworming programme in western Kenya: a pure replication. Int J Epidemiol. 2015;44:1572–80.
Ffrench-Constant RH. The molecular genetics of insecticide resistance. Genetics. 2013;194:807–15.
Prichard RK. Markers for benzimidazole resistance in human parasitic nematodes? Parasitology. 2007;134:1087–92.
Vercruysse J, Levecke B, Prichard R. Human soil-transmitted helminths: implications of mass drug administration. Curr Opin Infect Dis. 2012;25:703–8.
Lalli C, Guidi A, Gennari N, Altamura S, Bresciani A, Ruberti G. Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9:e0003484.
Paveley RA, Mansour NR, Hallyburton I, Bleicher LS, Benn AE, Mikic I, et al. Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis. 2012;6:e1762.
Beisel CL, Gomaa AA, Barrangou R. A CRISPR design for next-generation antimicrobials. Genome Biol. 2014;15:516.
Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32:1146–50.
Hashimoto M, Nara T, Hirawake H, Morales J, Enomoto M, Mikoshiba K. Antisense oligonucleotides targeting parasite inositol 1,4,5-trisphosphate receptor inhibits mammalian host cell invasion by Trypanosoma cruzi. Sci Rep. 2014;4:4231.
Doolan DL, Apte SH, Proietti C. Genome-based vaccine design: the promise for malaria and other infectious diseases. Int J Parasitol. 2014;44:901–13.
Croft SL, Olliaro P. Leishmaniasis chemotherapy—challenges and opportunities. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2011;17:1478–83.
González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, et al. Designing and reporting clinical trials on treatments for cutaneous Leishmaniasis. Clin Infect Dis. 2010;51:409–19.
Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs. 2002;3:538–44.
Van Bocxlaer K, Yardley V, Murdan S, Croft SL. Drug permeation and barrier damage in Leishmania-infected mouse skin. J Antimicrob Chemother. 2016;doi:10.1093/jac/dkw012.